Conduit Pharmaceuticals Inc. has received notice from the United States Securities and Exchange Commission (SEC) regarding the effectiveness of its S-3 Form. The Form S-3, with file number 333-283449, became effective on December 6, 2024, at 4:30 P.M.This development signifies that the company's registration statement has been approved by the SEC, potentially allowing Conduit Pharmaceuticals to offer and sell securities to the public. The S-3 Form is commonly used by public companies to register securities for future public offerings, providing the company with increased flexibility in accessing capital markets.

Conduit Pharmaceuticals Inc. has received notice from the United States Securities and Exchange Commission (SEC) regarding the effectiveness of its S-3 Form. The Form S-3, with file number 333-283449, became effective on December 6, 2024, at 4:30 P.M.This development signifies that the company's registration statement has been approved by the SEC, potentially allowing Conduit Pharmaceuticals to offer and sell securities to the public. The S-3 Form is commonly used by public companies to register securities for future public offerings, providing the company with increased flexibility in accessing capital markets.